English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  The safety of front‐line chemotherapies for the treatment of extensive stage small‐cell lung cancer ( ED‐SCLC ) is uncertain. We carried out a network meta‐analysis to compare the toxicity of different therapies for  ED‐SCLC .    Methods  We searched  EMBASE ,  PubMed ,  CENTRAL  and  clinicaltrials.gov . We performed network meta‐analysis on hematological (anemia, leukopenia, neutropenia, and thrombocytopenia) and non‐hematological toxicities (diarrhea, infection, and nausea and vomiting).    Results  Nine studies with 2317 patients were included. Etoposide with carboplatin ( EC ) was associated with a higher incidence of anemia (odds ratio [ OR ] 2.02, 95% confidence interval [ CI ] 1.13–3.63), leukopenia ( OR  2.67, 95%  CI  1.25–5.72), neutropenia ( OR  12.08, 95%  CI  2.13–68.66), and thrombocytopenia ( OR  2.73, 95%  CI  1.27–5.85) compared with irinotecan with carboplatin ( IC ). Similarly, etoposide with cisplatin ( EP ) was associated with a higher incidence of anemia ( OR  1.70, 95%  CI  1.13–2.56), leukopenia ( OR  2.65, 95%  CI  1.34–5.28), neutropenia ( OR  5.70, 95%  CI  2.93–11.10), and thrombocytopenia ( OR  3.26, 95%  CI  1.66–6.38) compared with irinotecan with cisplatin ( IP ).  EC  was associated with a lower incidence of diarrhea ( OR  0.26, 95%  CI  0.10–0.68) compared with  IC,  and  EP  was associated with a lower incidence of diarrhea ( OR  0.09, 95%  CI  0.03–0.25) and nausea and vomiting ( OR  0.53, 95%  CI  0.33–0.84) than  IP .    Conclusions  Hematological toxicities were most common in  EC ‐treated patients, while the lowest incidence occurred with  IP  treatment. The  IP  regimen was associated with the highest incidence of toxicities of the digestive tract, while the lowest incidence occurred with  EC  treatment.

thoracic cancer

Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small‐cell lung cancer patients with extensive disease:  A  network meta‐analyses